Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON39013
NL-OMON39013
Recruiting
Phase 4

ong term prospective observational cohort study on the safety and efficacy of abatacept subcutaneus in the daily clinical practice of rheumatoid arthritis - Abatacept subcutaneous in rheumatoid arthritis

Jan van Breemen Instituut0 sites100 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsInflammatory rheumatic disease10023213

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Inflammatory rheumatic disease
Sponsor
Jan van Breemen Instituut
Enrollment
100
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational non invasive

Investigators

Sponsor
Jan van Breemen Instituut

Eligibility Criteria

Inclusion Criteria

  • •Patients \* 18 years old at treatment initiation
  • •Patients informed and accepting to participate (Written informed consent)
  • •Patients diagnosed with established moderate to severe active RA as per the 1987 ACR criteria/2010 ACR/EULAR Rheumatoid Arthritis Classification Criteria
  • •Patients who at their physician\*s discretion are initiated with abatacept SC.

Exclusion Criteria

  • •Patients currently participating in any interventional clinical trial in RA
  • •Contraindications against abatacept SC treatment.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 4
ong term prospective observational cohort study of the safety and efficacy of golimumab in the daily clinical practice of rheumatoid arthritis with emphasis on the lipid profileinflammatory rheumatic disease1000381610023213
NL-OMON36406Jan van Breemen Instituut200
Recruiting
Phase 4
ong term prospective observational cohort study of the safety and efficacy of certolizumab pegol in the daily clinical practice of rheumatoid arthritis with emphasis on the lipid profileinflammatory rheumatic disease1000381610023213
NL-OMON36770Jan van Breemen Instituut200
Completed
Not Applicable
ong term, prospective, observational cohort study evaluating the safety profile in patients with highly active relapsing multiple sclerosis (RMS) newly started on oral cladribineG35.9
DRKS00015267Merck KGaA1,115
Not yet recruiting
Not Applicable
Rate of multidrug resistance to antimicrobial drugs in paediatric neurointensive care patientsHealth Condition 1: Z163- Resistance to other antimicrobialdrugs
CTRI/2019/10/021721All India institute of medical sciences
Completed
Not Applicable
Venous thromboembolism in care homes
ISRCTN80889792niversity of Birmingham (UK)1,000